

**PATENT**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES PATENT AND TRADEMARK OFFICE VIA THE  
ELECTRONIC FILING SYSTEM ON:

July 14, 2008

/Janet Sherrill/  
SIGNATURE

July 14, 2008

DATE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants	:	Arnold I. Caplan et al.
Serial No.	:	10/550,590
Filing Date	:	22 September 2005
For	:	CELL TARGETING METHODS AND COMPOSITIONS
Group Art Unit	:	1633
Examiner	:	ILEANA POPA
Attorney Docket No.	:	CWR-7781PCT/US

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**ELECTION REQUIREMENT**

Sir:

In response to the Requirement for Election mailed on May 15, 2008, the Applicants hereby elect, without traverse, the invention of Group 1, drawn to a cell delivery composition, for further prosecution.

It is respectively submitted that claims 1-4, 6, 8, 9, 11, 13-18, 20-26, 29, 32-39, 41, 45-48, 50, 52, 54-59, 61-67, 70, 73-80, 82, 84-89, 190, and 191 read on the elected invention.

In addition, Applicants have elected distinct species of progenitor cell, markers, target tissue, bioactive factor, and targeting tissue. The species are consistent with each other for the purpose of the examination.

The Applicants elect the distinct species of targeting moieties selected from the group consisting of antibodies.

The Applicants also elect the distinct species of a delivery method selected from the group consisting of delivery via injection into the target tissue.

The Applicants also elect the species of progenitor cells selected from the group consisting of totipotent stem cells, pluripotent stem cells, multipotent stem cells, mesenchymal stem cells, embryonic stem cells and embryonic germ cells.

The Applicants also elect the species of markers selected from the group consisting of CD34, CD45, c-kit, Sca-1, Stro-1, Thy-1, and Collagen types II or IV.

The Applicants also elect the species of target tissues selected from the group consisting of cartilage.

The Applicants further elect the species of bioactive factors selected from the group consisting of a transforming growth factor, bone morphogenetic proteins, a cartilage derived morphogenic protein, a growth differentiation factor, a growth hormone, an interleukin, a connective tissue growth factor, a chemokine, and a Wnt protein.

Claims readable on the elected species include claims 1-4, 6, 8, 9, 11, 13-18, 26, 29, 39, 41, 45-48, 50, 52, 54-59, 67, 70, 80, 82, 85, 190, and 191.

An early action on the merits of claims 1-4, 6, 8, 9, 11, 13-18, 26, 29, 39, 41, 45-48, 50, 52, 54-59, 67, 70, 80, 82, 85, 190, and 191 is respectfully requested.

Please charge any deficiency or credit any overpayment in the fees for this  
Election Requirement to our Deposit Account No. 20-0090.

Respectfully submitted,

/Richard A. Sutkus/

Richard A. Sutkus

Reg. No. 43,941

TAROLLI, SUNDHEIM, COVELL,  
& TUMMINO L.L.P.  
1300 East Ninth Street, Suite 1700  
Cleveland, Ohio 44114  
Phone: (216) 621-2234  
Fax: (216) 621-4072  
Customer No.: 68,705